Loading people...
Francisco Gimenez is a Partner at 8VC, a leading venture capital firm. He is known for his expertise in identifying and supporting innovative technology companies, particularly in the enterprise software, AI, data infrastructure, and developer tools sectors.
Francisco Gimenez primarily invests in companies focused on enterprise software, artificial intelligence (AI), machine learning (ML), data infrastructure, and developer tools. He seeks out startups building scalable platforms to solve complex business challenges.
Francisco Gimenez works as a Partner at 8VC, a prominent venture capital firm.
Francisco Gimenez serves as a distinguished Partner at 8VC, a prominent venture capital firm known for its strategic investments in foundational technology companies. In his role at 8VC, Gimenez is instrumental in identifying, evaluating, and nurturing startups that are poised to redefine industries through technological innovation. His primary investment focus areas include enterprise software, artificial intelligence (AI), machine learning (ML), data infrastructure, and developer tools. He is particularly passionate about companies that build robust, scalable platforms designed to solve complex challenges for businesses across various sectors.
Gimenez brings a wealth of experience and a deep understanding of the technology landscape to his work at 8VC. Prior to his tenure as a Partner, he served as a Principal at the firm, where he honed his expertise in venture capital and strategic growth. Before joining 8VC, Francisco held significant roles at Palantir Technologies, a pioneering data analytics company. At Palantir, he contributed across various functions, including product development, business development, and engineering. This diverse operational background provided him with invaluable insights into the intricacies of building and scaling sophisticated technology products from the ground up. His early career also includes co-founding The Data Collective, further solidifying his commitment to leveraging data for transformative impact.
His academic foundation is equally strong, holding a Bachelor of Science degree in Computer Science from Stanford University. This rigorous technical background underpins his ability to deeply understand the technological merits and market potential of the companies he evaluates. At 8VC, Francisco Gimenez is known for his hands-on approach, working closely with founders to navigate product-market fit, accelerate growth, and build enduring businesses. He is a strong advocate for companies that are not just innovating, but also creating sustainable competitive advantages through superior technology and execution.
While specific individual investments are often part of a broader firm strategy, Francisco's influence is evident in 8VC's robust portfolio within the enterprise and data sectors. He actively seeks out entrepreneurs who are developing the next generation of infrastructure and applications that empower businesses to operate more efficiently, intelligently, and securely. His contributions help solidify 8VC's position as a leader in backing companies that are shaping the future of enterprise technology, from advanced AI solutions to critical data management platforms and essential developer tools.
Francisco Gimenez is a Partner at 8VC based in San Francisco, California, where he leads investments across the healthcare, bio-IT, and enterprise AI sectors. Before joining the venture capital firm in 2016, he served as a Resident Data Scientist at Formation 8 and previously founded Catenus Science, an independent data science consulting and recruiting firm. Gimenez earned a PhD in Biomedical Informatics from Stanford University and a BS in Electrical Engineering and Computer Sciences from UC Berkeley. During his time at Stanford, he was a Ruth L Kirchstein Fellow, won the 2014 Martin Epstein award, and served as the 2015 commencement speaker for the School of Medicine. Currently holding multiple board director seats, he leverages his extensive academic research in machine learning and medical imaging to identify promising early-stage computational biology and digital health technology startups.
